Abstract:Introduction Genotyping plays an important role in the diagnosis, risk stratification and treatment response surveillance of lymphoma, a disease with considerable heterogeneity in clinical and pathological characteristics. To date, tumor tissue biopsy based genotyping is still considered as gold standard in lymphoma, but its application is hampered by the invasive nature and imperfect performance in capturing spatial and temporal tumor heterogeneity. Circulating tumor DNA (ctDNA), which is shed into peripheral blood by apoptotic or necrotic tumor cells, has shown the potential as a noninvasive alternative to tumor tissue DNA (tDNA) for molecular profiling. Many efforts have been made to investigate the feasibility of ctDNA based on next-generation sequencing (NGS) in lymphoma, but most of the studies were conducted in Caucasian population and limited to B-cell lymphoma patients. In the present study, we evaluated the performance of plasma-derived ctDNA against tDNA based genotyping across multiple lymphoma subtypes. Methods Between 4/2021 and 5/2023, a total of 110 patients were enrolled in this study. Matched tumor tissue biopsies and peripheral blood were collected at diagnosis. Both tDNA and ctDNA were extracted and subjected to a targeted capture NGS assay covering the entire coding region or recurrently mutated region of 196 genes. The mean coverage depth was 2431x and 2513x for tDNA and ctDNA, respectively. The limit of detection (LOD) was 1% and 0.5% for tDNA and ctDNA, respectively. Results The enrolled cohort comprised of 63 (57.3%) male and 47(42.7%) female patients, with a median age of 58 years old (range 1.25-89). Among the 110 patients, the most prevalent subtype is diffuse large B-cell lymphoma (DLBCL,n=45), following by angioimmunoblastic T-cell lymphoma (AITL, n=16), anaplastic large cell lymphoma (ALCL, n=13) , mantle cell lymphoma (MCL, n=10), follicular lymphoma (FL, n=9), primary mediastinal large B-cell lymphoma (PMBL, n=9), extranodal natural killer/T cell lymphoma (ENKTL, n=4), and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS, n=4). For further analysis, DLBCL, MCL, FL and PMBL were categorized as B-cell lymphoma group (n=73), while AITL, ALCL, ENKTL and PTCL-NOS were categorized as T-cell lymphoma group (n=37). Mutations were detected in 109(99.10%)tDNA and 110(100%)ctDNA, respectively. A total of 1586 mutations involving 177 genes were detected in tDNA, and the median number of mutations per sample was 12 (range 0-62), with KMT2D (39.09%), KMT2C (30.90%), IGLL5 (30.00%), TET2 (25.45%) and TP53 (20.90%) being the top 5 mutated genes. For ctDNA, a total of 1750 mutations involving 178 genes were detected and the median number of mutations per sample was 14 (range 2-63), with KMT2D (37.27%), KMT2C (29.09%), IGLL5 (27.27%), TET2 (25.45%) and DNMT3A (27.27%) being the top 5 mutated genes. To determine the concordance of mutations detected in tDNA and ctDNA, sensitivity was calculated utilizing tDNA as gold standard. The overall sensitivity of ctDNA based genotyping was 85.39% (95%CI: 82.36%-88.41%), with B-cell lymphoma showing a slightly higher sensitivity than T-cell lymphoma (86.17%, 95%CI: 83.51%-88.83% vs. 83.84%, 95%CI: 76.30%-91.32%). In terms of subtypes, PTCL-NOS exhibited the highest sensitivity (89.58%, 95%CI: 56.43%-122.73%, while AITL exhibited the lowest sensitivity (78.53%, 95%CI: 64.09%-92.97%) (Figure 1A). In addition, the difference of mutational spectrum between B-cell lymphoma and T-cell lymphoma was precisely depicted by ctDNA based genotyping. We discovered mutations in TET2, RHOA, and PLCG1 were significantly present in T-cell lymphoma, while mutations in MYD88, CD79B, CARD11, CREBBP, MYC, PIM1, IGLL5, ATM, SOCS1 and HIST1HIE were significantly enriched in B-cell lymphoma (Figure 1B). Conclusion In the present study, recurrent mutations across a variety of lymphoma subtypes were identified by ctDNA based genotyping, which were in high concordance with tDNA based genotyping. These data demonstrated that ctDNA based genotyping is a reliable noninvasive alternative to tumor tissue biopsy for molecular profiling of lymphoma patients, especially for patients whose tissues are not accessible for genotyping.

Evaluation of genome-wide genotyping concordance between tumor tissues and peripheral blood

Quality and concordance of genotyping array data of 12,064 samples from 5840 cancer patients.

Concordance of Genomic Alterations between Circulating Tumor DNA and Matched Tumor Tissue in Chinese Patients with Breast Cancer

Concordance Study of a 520-Gene Next-Generation Sequencing-Based Genomic Profiling Assay of Tissue and Plasma Samples

Concordance of genomic mutations between tissue and ctDNA in non-small cell lung cancer: impact of time interval stratified by stage, smoking history and treatment

Validation of a 90-Gene Assay for Tissue Origin Diagnosis of Brain Metastases.

Heterogeneous Mutation Pattern in Tumor Tissue and Circulating Tumor DNA Warrants Parallel NGS Panel Testing

Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.

Comparison of Plasma Ctdna from the Portal and Peripheral Veins of Resectable CRC Patients.

Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer.

Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort

The Discordance of Gene Mutations between Circulating Tumor Cells and Primary/Metastatic Tumor.

The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.

The Discordance of Gene Mutations Between Circulating Tumor Cells and Primary/Metastatic Tumor

Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer

Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice

Comparison of the Somatic Mutations Between Circulating Tumor DNA and Tissue DNA in Chinese Patients with Non-Small Cell Lung Cancer.

Consistency evaluation of lung adenocarcinoma tissue and circulating tumor cells related gene mutation detection based on multi-site immunomagnetic beads

Comparative Analysis of the Representative Value of Somatic Mutation Profiles Derived from Ctdna and Other Updated Lung Tumor Biopsy Alternative in Non-Resectable Non-Small Cell Lung Cancer Patients.

Supplementary Data from Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in over 5,000 Chinese Patients with Lung Cancer

Validation of Circulating Tumor DNA As an Alternative to Tumor Tissue Biopsy in Genotyping across Multiple Lymphoma Subtypes